Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study.

Purpose: The PURE-01 clinical trial reported the use of neoadjuvant treatment with pembrolizumab prior to radical cystectomy (RC) in patients with muscle-invasive bladder. Specific molecular subtypes and immune signatures were reported to be associated with a favorable survival. However, reports on the detailed tumor biology of patients relapsing after neoadjuvant pembrolizumab are lacking.

Opiliofauna (ARACHNIDA: OPILIONES) of the Atlantic Forest in the state of Paraná, Brazil.

Opiliones are arachnids that provide different services in terrestrial ecosystems, especially in tropical forests, which justifies inventory studies to better understand the occurrence and distribution of these arthropods in Brazil, since little is known about the harvestmen fauna in Conservation Units such as in the state of Paraná. In this context, the objective of the present study was to survey the harvestmen fauna at the Iguaçu National Park (PARNA) and in the Bela Vista Biological Refuge (BVBR), from September 2021 to May 2022, using a sampling effort of 40 hours in the BVBR, and 66 hours at the PARNA Iguaçu. Ten species/morphospecies were recorded, highlighting a new occurrence for Brazil, the species Opisthoplatus vegetus.

Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.

Objective: To evaluate the predictive capability of the pre- and post-pembrolizumab Vesical Imaging-Reporting and Data System (VI-RADS) to identify ypT0N0 or ypT≤1N0 response in muscle-invasive bladder cancer (MIBC) within the PURE-01 trial (ClinicalTrials.gov identifier: NCT02736266).

Patients And Methods: Patients were staged with bladder multiparametric magnetic resonance imaging (mpMRI) before and after treatment (three cycles of pembrolizumab) prior to radical cystectomy (RC).

Xylooligosaccharides: A Bibliometric Analysis and Current Advances of This Bioactive Food Chemical as a Potential Product in Biorefineries' Portfolios.

Xylooligosaccharides (XOS) are nondigestible compounds of great interest for food and pharmaceutical industries due to their beneficial prebiotic, antibacterial, antioxidant, and antitumor properties. The market size of XOS is increasing significantly, which makes its production from lignocellulosic biomass an interesting approach to the valorization of the hemicellulose fraction of biomass, which is currently underused. This review comprehensively discusses XOS production from lignocellulosic biomass, aiming at its application in integrated biorefineries.

Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.

Context: Predictive and prognostic biomarkers in the perioperative treatment of muscle-invasive bladder cancer (MIBC) are an unmet need. Circulating tumor DNA (ctDNA) holds promise as a biomarker in this setting.

Objective: To review the evidence of ctDNA as a prognostic and predictive biomarker in the perioperative treatment of MIBC.